Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

被引：0
|
作者：
Dobric, N. [1 ]
Dandachi, N. [1 ]
Klocker, E. V. [1 ]
Suppan, C. [1 ]
Graf, R. [2 ]
Hasenleithner, S. [2 ]
Jost, P. J. [1 ]
Heitzer, E. [2 ]
Balic, M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Human Genet, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
491P
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [21] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [22] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [23] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
  • [24] HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (06)
  • [25] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [26] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [27] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [28] COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
    Altundag, K.
    Basaran, G.
    Oksuzoglu, B.
    Oven, B.
    Ozguroglu, M.
    Aydin, D.
    Hacibedel, B.
    Helvacioglu, K.
    Tuna, E.
    Tatar, M.
    VALUE IN HEALTH, 2016, 19 (03) : A146 - A146
  • [29] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [30] Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
    Modi, S.
    Byng, D.
    Zhang, S.
    Xiong, Y.
    Hunter, S.
    Struebing, A.
    Dunton, K.
    Mbanya, Z.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2024, 35 : S386 - S386
12345